Julie Clark
Chief Tech/Sci/R&D Officer bei OPTHEA LIMITED
Profil
Julie Clark is currently the Senior Vice President-Clinical Development at Opthea Ltd.
She previously worked as an Associate Director-Medical affairs at Regeneron Pharmaceuticals, Inc. from 2011 to 2012.
Dr. Clark also held positions as a Medical Director at Novartis Corp., Thrombogenics, Inc., and Adverum Biotechnologies, Inc. She was also the Chief Medical Officer at Adverum Biotechnologies, Inc. Additionally, Dr. Clark served as the Vice President-Clinical Development at IVERIC bio, Inc. Dr. Clark received her undergraduate and doctorate degrees from Wake Forest School of Medicine and her undergraduate degree from Wake Forest University.
She also obtained a graduate degree from The Johns Hopkins University.
Aktive Positionen von Julie Clark
| Unternehmen | Position | Beginn |
|---|---|---|
| OPTHEA LIMITED | Chief Tech/Sci/R&D Officer | 01.02.2024 |
Ehemalige bekannte Positionen von Julie Clark
| Unternehmen | Position | Ende |
|---|---|---|
| ADVERUM BIOTECHNOLOGIES, INC. | Chief Tech/Sci/R&D Officer | 22.10.2021 |
| REGENERON PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01.10.2012 |
| IVERIC BIO, INC. | Corporate Officer/Principal | - |
Thrombogenics, Inc.
 Thrombogenics, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Oxurion NV, Thrombogenics, Inc. operates as a biotechnology company that delivers innovative treatments for diseases of the back of the eye, with a focus on diabetic eye disease. The private company is based in New York, NY. | Chief Tech/Sci/R&D Officer | - |
Novartis Corp.
 Novartis Corp. Pharmaceuticals: MajorHealth Technology Novartis Corp. manufactures pharmaceuticals, vaccines, consumer health, generics, eye care and animal health products. It manufactures drugs for oncology, hypertension, diabetes, cancer and cardiovascular diseases. The company was founded on November 15, 1996 and is headquartered in New York, NY. | Corporate Officer/Principal | - |
Ausbildung von Julie Clark
| Wake Forest School of Medicine | Doctorate Degree |
| Wake Forest University | Undergraduate Degree |
| The Johns Hopkins University | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| REGENERON PHARMACEUTICALS, INC. | Health Technology |
| OPTHEA LIMITED | Health Technology |
| ADVERUM BIOTECHNOLOGIES, INC. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Novartis Corp.
Novartis Corp. Pharmaceuticals: MajorHealth Technology Novartis Corp. manufactures pharmaceuticals, vaccines, consumer health, generics, eye care and animal health products. It manufactures drugs for oncology, hypertension, diabetes, cancer and cardiovascular diseases. The company was founded on November 15, 1996 and is headquartered in New York, NY. | Health Technology |
IVERIC bio, Inc.
 IVERIC bio, Inc. Pharmaceuticals: GenericHealth Technology IVERIC bio, Inc. operates as a biopharmaceutical company. The firm engages in discovering, developing and commercializing novel therapeutics to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. Its product candidates include Zimura and Gene Therapy. The company was founded by David R. Guyer and Samir Chandrakant Patel on January 5, 2007 and is headquartered in Parsippany, NJ. | Health Technology |
Thrombogenics, Inc.
Thrombogenics, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Oxurion NV, Thrombogenics, Inc. operates as a biotechnology company that delivers innovative treatments for diseases of the back of the eye, with a focus on diabetic eye disease. The private company is based in New York, NY. | Commercial Services |
